breast cancer chemotherapy: results of a feasibility intervention study . Oncol Nurs Forum 2003 ; 30 : 513 – 522 . 9 Demetri GD Kris M Wade J . Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of
Search Results
Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg
Daniel Shasha, Pierre Cremieux, and Louis Harrison
. Impact of tumor hypoxia and anemia on radiation therapy outcomes . Oncologist 2002 ; 7 : 492 – 508 . 26 Demetri G Kris M Wade J , for the Procrit Study Group . Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is
Rodger J. Winn
References 1 Littlewood TJ Bajetta E Nortier JW . Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo
Carmen P. Escalante, Ellen Manzullo, and Rosalie Valdres
toward guidelines for the management of fatigue . Oncology 1998 ; 12 : 369 – 377 . 4 Demetri GD Kris M Wade J Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type
Jeffrey A. Gilreath, Daniel S. Sageser, James A. Jorgenson, and George M. Rodgers
. 4. Henry DH Dahl NV Auerbach M . Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy . Oncologist 2007 ; 12 : 231 – 242 . 5
John A. Glaspy
. Crawford J Cella D Cleeland CS . Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy . Cancer 2002 ; 95 : 888 – 895 . 4. Cella D Zagari MJ Vandoros
John A. Glaspy
The author has received research support from Amgen, Ortho Biotech, and Hoffman La Roche. References 1 Cella D Zagari MJ Vandoros C . Epoetin alfa treatment results in clinically significant improvements in quality of life in
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Featured Updates to the NCCN Guidelines
Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, and Lenora A. Pluchino
-bmez were recently included in the NCCN Guidelines as appropriate substitutions for originator filgrastim and pegfilgrastim, respectively, for prevention of FN. In addition, epoetin alfa-epbx has also been included as an appropriate substitute for epoetin
John Glaspy
FDA approved epoetin alfa, the rEPO used in clinical trials in the United States, for the treatment of patients with cancer-related anemia undergoing chemotherapy based on the reported reduction in red cell transfusions. Subsequently, another cloned
George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, and Alva B. Weir III
produced in the kidneys. First introduced in 1989, ESAs are a synthetic, recombinant human erythropoietin that can stimulate erythropoiesis in patients with low RBC levels. Currently, 2 ESAs are available in the United States: epoetin alfa and darbepoetin
